Institutional equity analyst consensus forecasts for Avacta Group plc (LSE: AVCT) point toward a 12-month average price target hovering around 99.00p (with independent analyst estimates ranging between a low of 60.00p and a high of 84.00p to 99.00p), reflecting projected upside driven by clinical trial milestones within its oncology pipeline.